196 related articles for article (PubMed ID: 31606091)
1. Preparation of a new construct of human histone deacetylase 8 for the crystallization of enzyme-inhibitor complexes.
Porter NJ; Christianson DW
Methods Enzymol; 2019; 626():561-585. PubMed ID: 31606091
[TBL] [Abstract][Full Text] [Related]
2. Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8.
Porter NJ; Christianson DW
ACS Chem Biol; 2017 Sep; 12(9):2281-2286. PubMed ID: 28846375
[TBL] [Abstract][Full Text] [Related]
3. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
[TBL] [Abstract][Full Text] [Related]
5. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.
Ortore G; Di Colo F; Martinelli A
J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
[TBL] [Abstract][Full Text] [Related]
7. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
8. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
Singh RK; Suzuki T; Mandal T; Balsubramanian N; Haldar M; Mueller DJ; Strode JA; Cook G; Mallik S; Srivastava DK
Biochemistry; 2014 Dec; 53(48):7445-58. PubMed ID: 25407689
[TBL] [Abstract][Full Text] [Related]
9. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
[TBL] [Abstract][Full Text] [Related]
10. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
[TBL] [Abstract][Full Text] [Related]
11. Inhibition and mechanism of HDAC8 revisited.
Chen K; Zhang X; Wu YD; Wiest O
J Am Chem Soc; 2014 Aug; 136(33):11636-43. PubMed ID: 25060069
[TBL] [Abstract][Full Text] [Related]
12. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
Christianson DW
Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
[TBL] [Abstract][Full Text] [Related]
13. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.
Thangapandian S; John S; Sakkiah S; Lee KW
Eur J Med Chem; 2010 Oct; 45(10):4409-17. PubMed ID: 20656379
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases.
Cole KE; Dowling DP; Boone MA; Phillips AJ; Christianson DW
J Am Chem Soc; 2011 Aug; 133(32):12474-7. PubMed ID: 21790156
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.
Heimburg T; Kolbinger FR; Zeyen P; Ghazy E; Herp D; Schmidtkunz K; Melesina J; Shaik TB; Erdmann F; Schmidt M; Romier C; Robaa D; Witt O; Oehme I; Jung M; Sippl W
J Med Chem; 2017 Dec; 60(24):10188-10204. PubMed ID: 29190092
[TBL] [Abstract][Full Text] [Related]
16. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes.
Lombardi PM; Cole KE; Dowling DP; Christianson DW
Curr Opin Struct Biol; 2011 Dec; 21(6):735-43. PubMed ID: 21872466
[TBL] [Abstract][Full Text] [Related]
17. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.
Somoza JR; Skene RJ; Katz BA; Mol C; Ho JD; Jennings AJ; Luong C; Arvai A; Buggy JJ; Chi E; Tang J; Sang BC; Verner E; Wynands R; Leahy EM; Dougan DR; Snell G; Navre M; Knuth MW; Swanson RV; McRee DE; Tari LW
Structure; 2004 Jul; 12(7):1325-34. PubMed ID: 15242608
[TBL] [Abstract][Full Text] [Related]
18. Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.
Muth M; Jänsch N; Kopranovic A; Krämer A; Wössner N; Jung M; Kirschhöfer F; Brenner-Weiß G; Meyer-Almes FJ
Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):577-585. PubMed ID: 30611847
[TBL] [Abstract][Full Text] [Related]
19. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
Osko JD; Christianson DW
Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
[TBL] [Abstract][Full Text] [Related]
20. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
